Navigation Links
Penn bioengineers create simulator to test blood platelets in virtual heart attacks
Date:6/20/2010

PHILADELPHIA - A team of bioengineers from the University of Pennsylvania Institute for Medicine and Engineering have trained a computer neural network model to accurately predict how blood platelets would respond to complex conditions found during a heart attack or stroke.

Using an automated, robotic system, they exposed human blood platelets to hundreds of different combinations of biological stimuli like those experienced during a heart attack. This was done by fingerprinting each platelet sample with 34,000 data points obtained in response to all possible pairs of stimuli.

The team applied the system to predict intracellular calcium signaling responses of human platelets to any combination of up to six different agonists used at different dosages and even applied at different times. The model predicted platelet responses accurately, even distinguishing between 10 blood donors, demonstrating an efficient approach for predicting complex chemical responses in a patient-specific disease milieu.

The strategy involves selecting molecules that react with blood platelets under high-risk situations, such as a heart attack, measuring the cellular responses to all pairwise combinations of stimuli in a high-throughput manner and then training a two-layer, nonlinear, neural network with the measured cellular responses. For platelets, it was discovered that the complexity of integrating numerous signals can be built up from the responses to simpler conditions involving only two stimuli.

"With patient-specific computer models, it is now possible to predict how an individual's platelets would respond to thousands of 'in silico' heart-attack scenarios," said Scott L. Diamond, professor of chemical and biomolecular engineering and the director of the Penn Center for Molecular Discovery. "With this information we can identify patients at risk of thrombosis or improve upon current forms of anti-platelet therapies."

The research team developed its experimental/computational technique, called Pairwise Agonist Scanning, or PAS, to define platelet response to combinations of agonists, chemicals that bind in this case to platelet cells, initiating a cellular response. Future research would include the application of PAS to clinical stimuli that platelets encounter such as epinephrine, serotonin and nitric oxide, which would map a major portion of the entire platelet response. The use of PAS with certain pharmacological agents would allow further assessment of individual clinical risk, or sensitivity to therapy.

Platelet cells respond in a patient-specific manner to multiple signals, and their reaction to thrombotic signals is central to the 1.74 million heart attacks and strokes, 1.115 million angiograms and 0.652 million stent placements in the United States each year. For Diamond, platelets are also ideal cellular systems for quantifying the effects of multiple signaling pathways because they are anucleate, easily obtained from donors and amenable to automated liquid handling. Few experimental or computational tools are available for building a global understanding of how the platelet integrates multiple stimuli present at varying levels.

Researchers working in systems biology seek to understand blood as a reactive biological fluid whose function changes through a variety of physical and chemical stimuli such as hemodynamics, vessel-wall characteristics, platelet metabolism, numerous coagulation factors in plasma and small molecules released during thrombosis.

Because platelet cells respond to numerous signals and chemical doses and integrate their responses to these stimuli, efficient and speedy computational methods are needed to survey such high-dimensional systems. Evaluating the cellular response to merely pairs of stimuli offers a direct and rapid sampling of the cellular response, which can be built up to predict even more complex situations and may eventually lead to a predictive clinical tool for cardiovascular disease.


'/>"/>

Contact: Jordan Reese
jreese@upenn.edu
215-573-6604
University of Pennsylvania
Source:Eurekalert

Related biology news :

1. Bioengineers at University of Pennsylvania devise nanoscale system to measure cellular forces
2. UC San Diego bioengineers fill holes in science of cellular self-organization
3. New method developed by UC San Diego bioengineers gives regenerative medicine a boost
4. Bioengineers succeed in producing plastic without the use of fossil fuels
5. MIT creates 3-D images of living cell
6. Newly created cancer stem cells could aid breast cancer research
7. Natural insecticide re-created in the lab
8. Auto immune response creates barrier to fertility; could be a step in speciation
9. Researchers develop simple method to create natural drug products
10. Using evolution, UW team creates a template for many new therapeutic agents
11. Cogent Systems and Northrop Grumman Reach Agreement to Settle Automated Fingerprint Identification Technology Suit and Create Strategic Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2017)... VIEW, Calif. , March 9, 2017 ... 23andMe , the leading personal genetics company, are using ... now provide customers with personalized nutrition plans that consider ... but also genetic markers impacting how their body may ... food decision support platform uses biometrics such as Body ...
(Date:3/2/2017)... , March 2, 2017 Summary This ... Perrigo and its partnering interests and activities since 2010. ... Read the ... and Alliance since 2010 report provides an in-depth insight into ... sciences companies. On demand company reports are prepared ...
(Date:3/1/2017)... Mass. , March 1, 2017  Aware, Inc. ... services, announced that Richard P. Moberg has ... and co-President and Chief Financial Officer and Treasurer of ... continue to serve as a member of the Board ... Russell , Aware,s co-Chief Executive Officer and co-President, General ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... 23, 2017 In today,s pre-market ... in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), ... MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." ... report at: ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a ... Biobank and GSK to generate genetic sequence data from the ... will enable researchers to gain valuable insights to support advances ... of serious and life threatening diseases. ... Genetic evidence has revolutionized ...
(Date:3/22/2017)...  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... address significant unmet medical needs in rare diseases, ... ended December 31, 2016. "2016 ... we broadened our pipeline and pursued our vision ... with an initial focus on endocrinology," said ...
(Date:3/22/2017)... March 22, 2017 Good Start Genetics, a ... eclipsed the 130 million covered lives mark through its ... Texas . With newly signed contracts ... to enjoy strong payor acceptance based on the quality ... and genetic counseling, its industry-leading customer care and support ...
Breaking Biology Technology: